MX9301821A - Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo. - Google Patents

Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.

Info

Publication number
MX9301821A
MX9301821A MX9301821A MX9301821A MX9301821A MX 9301821 A MX9301821 A MX 9301821A MX 9301821 A MX9301821 A MX 9301821A MX 9301821 A MX9301821 A MX 9301821A MX 9301821 A MX9301821 A MX 9301821A
Authority
MX
Mexico
Prior art keywords
biodegradable
polymerical
treatment
same
matrix system
Prior art date
Application number
MX9301821A
Other languages
English (en)
Inventor
Wouter E Roorda
Fred Ehnow
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of MX9301821A publication Critical patent/MX9301821A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0033—Additives activating the degradation of the macromolecular compound
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C08K5/34—Heterocyclic compounds having nitrogen in the ring
    • C08K5/3412—Heterocyclic compounds having nitrogen in the ring having one nitrogen atom in the ring
    • C08K5/3432—Six-membered rings
    • C08K5/3435—Piperidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las velocidades de degradación de polímeros biodegradables usados en formulaciones de surtido de fármaco de liberación sostenida son regulados por la incorporación en el polímero de un agente regulador, o modificador de velocidad de desgaste.
MX9301821A 1992-03-30 1993-03-30 Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo. MX9301821A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86064592A 1992-03-30 1992-03-30

Publications (1)

Publication Number Publication Date
MX9301821A true MX9301821A (es) 1994-03-31

Family

ID=25333681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301821A MX9301821A (es) 1992-03-30 1993-03-30 Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.

Country Status (6)

Country Link
US (1) US5571525A (es)
EP (1) EP0633907A1 (es)
AU (1) AU3941793A (es)
MX (1) MX9301821A (es)
WO (1) WO1993020134A1 (es)
ZA (1) ZA932273B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2177033C (en) * 1993-12-20 2000-06-27 Robert S. Honkonen Ph-modified polymer compositions with enhanced biodegradability
WO1998027962A2 (en) 1996-12-20 1998-07-02 Alza Corporation Injectable depot gel composition and method of preparing the composition
US6610764B1 (en) 1997-05-12 2003-08-26 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
US6867248B1 (en) 1997-05-12 2005-03-15 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
US6828357B1 (en) 1997-07-31 2004-12-07 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
DE69841579D1 (de) * 1997-12-22 2010-05-06 Metabolix Inc Polyhydroxyalkanoatzusammensetzungen mit kontrollierten Abbaugeschwindigkeiten
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
JP4554084B2 (ja) 1999-03-04 2010-09-29 テファ， インコーポレイテッド 組織操作のための生体吸収性、生体適合性ポリマー
US6503528B1 (en) * 1999-11-19 2003-01-07 Abbott Laboratories Polymeric compositions and a method of making the same
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
AU2002359407B2 (en) 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
MXPA05001242A (es) 2002-07-31 2005-06-08 Alza Corp Composiciones de deposito inyectable y usos de las mismas.
EP1539101B1 (en) 2002-07-31 2009-01-07 ALZA Corporation Injectable multimodal polymer depot compositions and uses thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP5596896B2 (ja) 2003-03-28 2014-09-24 イノヴェイショナル・ホールディングズ・エルエルシー 有益な薬剤の濃度勾配を有する、移植可能な医療装置の形成方法
CA2525132C (en) 2003-05-08 2011-06-28 Tepha, Inc. Polyhydroxyalkanoate medical textiles and fibers
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送***和活塞组件
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8779094B2 (en) 2008-11-16 2014-07-15 Board Of Regents, The University Of Texas System Low viscosity highly concentrated suspensions
AU2010298733B2 (en) 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9782957B2 (en) * 2011-08-24 2017-10-10 Covidien Lp Medical device films
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
WO2016025329A1 (en) 2014-08-15 2016-02-18 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
CA2969429C (en) 2014-12-11 2020-10-27 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送***及相关方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991766A (en) * 1973-05-31 1976-11-16 American Cyanamid Company Controlled release of medicaments using polymers from glycolic acid
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4122158A (en) * 1976-09-23 1978-10-24 Alza Corporation Topical therapeutic preparations
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4919939A (en) * 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4917892A (en) * 1988-06-28 1990-04-17 Temple University Encapsulated topical delivery system
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
JP2986509B2 (ja) * 1989-05-26 1999-12-06 三井化学株式会社 変性ポリエステル樹脂組成物、その製造方法、およびその用途
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
DK0568651T3 (da) * 1991-02-01 2002-08-05 Massachusetts Inst Technology Bionedbrydelige polymerblandinger til afgivelse af lægemidler
AU2154892A (en) * 1991-05-07 1992-12-21 Dynagen, Inc. A controlled, sustained release delivery system for treating drug dependency
PT659073E (pt) * 1992-09-10 2002-06-28 Childrens Medical Center Matrizes polimericas biodegradaveis para entrega sustentada de agentes anestesicos locais

Also Published As

Publication number Publication date
US5571525A (en) 1996-11-05
EP0633907A1 (en) 1995-01-18
AU3941793A (en) 1993-11-08
ZA932273B (en) 1993-11-26
WO1993020134A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
MX9301821A (es) Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.
DK0866816T3 (da) Lineær blokpolymer indeholdende urea- og urethangrupper, fremgangsmåde til fremstilling af lineære blokpolymerer samt anvendelse af blokpolymererne som implantater
BR9603619B1 (pt) composição de liberação sustentada.
BR9609176A (pt) Composi-{es de agente biolÄgico
BR9206408A (pt) Escova oral, matriz de liberação prolongada, processo para liberar um agente antimicrobiano de uma escova oral e para liberação de um agente antimicrobiano na boca de um animal e escova oral indicadora de desgaste
DE69424275D1 (de) Alkalische ophthalmische suspensionen
ES2063779T3 (es) Nuevos esteres de polisacaridos.
ES2177592T3 (es) Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
MX167175B (es) Sistema de entrega de drogas, con liberacion controlada, para la bolsa periodontal
HUT73197A (en) Polymer compositions, storage compositions, processes for producing thereof and articles produced therefrom
ZA915584B (en) Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
FI954989A (fi) Lääkelaastari
DK0797917T3 (da) Fremgangsmåde til desinfektion af luft med iod/harpiksbaseret desinfektionsmiddel og systemer til desinfektion af luftbårne mikroorganismer
FI953086A (fi) Superimukykyiset polymeerit ja niitä sisältävät tuotteet
ES2078216T3 (es) Metodo para preparar copolimeros radiales asimetricos.
ES2094781T3 (es) Composicion farmaceutica de microparticulas con liberacion controlada y su proceso de preparacion.
FI932761A (fi) Foerfarande foer framstaellning av aktiva substanser innehaollande mikropartiklar av hydrolytiskt nedbrytbara polymerer
ATE178620T1 (de) Polymerisate, deren herstellung und verwendung
ZA957578B (en) Implantable molded articles for the administration of active substances to plants
NO942396L (no) Preparat med vedvarende frigiving av anti-endotelin substans
DE69715191D1 (de) Verfahren zur Herstellung von Mikropartikeln
BR9307193A (pt) Processo para a preparação de uma formulação sólida de um agente de proteção de culturas e formulação sólida de agente de proteção de culturas
ES2138359T3 (es) Utilizacion de derivados de 1,4 dihidropiridina en la prevencion y la terapia de la degradacion arteroesclerosa de las paredes arteriales.
ES2187557T3 (es) Utilizacion de dextrano sustituido para el tratamiento de las lesiones del sistema nervioso y fracciones enriquecidas en heparano sulfato.
EP0480391A3 (en) Emulsion-free emulsion polymers, their production and their use in sustained-release pharmaceutical compositions